IONIS PHARMACEUTICALS INC — Director's Dealing 2019

Mar 20, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IONIS PHARMACEUTICALS INC (IONS)
CIK: 0000874015
Period of Report: 2019-03-18

Reporting Person: O'NEIL PATRICK R. (SVP Legal & General Counsel)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-03-18	Common Stock	M	28800	$61.57	Acquired	48473	Direct
2019-03-18	Common Stock	S	28800	$78.7912	Disposed	19673	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-03-18	Employee Stock Option (right to buy)	$61.57	M	28800	Acquired	2022-01-01	Common Stock (28800)	Direct

Footnotes

F1: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 8/29/2018.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.75 to $78.895, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.